Field efficacy study of a novel ready-to-use vaccine against mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm

Abstract

BackgroundThe primary objective of this study was to assess the efficacy, under field conditions, of a novel ready-to use Mycoplasma hyopneumoniae (M hyo) and Porcine circovirus type 2 (PCV2) combination vaccine given to piglets as one vaccination (1-shot) at 3 weeks of age. The study was carried out according to a controlled, randomised, and blinded design in a Greek pig herd with clinical M. hyo and subclinical PCV2 infection. Moreover, based on serology at the time of vaccination, the average PCV2 titre was 9.15 log2 and represented the level of maternally derived antibodies (MDA). In total 602 healthy suckling piglets, originating from 4 weekly farrowing batches were allocated randomly, within litters, to one of two groups. The pigs in one group were vaccinated with the test product and the other pigs were injected with saline.ResultsVaccination significantly reduced lesions of craneo-ventral pulmonary consolidation in vaccinated group [expressed as lung lesion score (LLS)] (Mixed model ANOVA: p < 0.0001). The mean LLS was 17.1 in the controls and 10.6 in the treatment group, respectively. The average daily weight gain (ADWG) during the finishing (54 g better in the treatment group) and whole study period (34 g better in vaccinated animals) was significantly greater in vaccinated than control pigs. The vaccinated pigs had a significant reduction of PCV2 viraemia when compared with the controls.ConclusionsThe test product was considered effective in the face of average MDA, based on significantly reduced severity of LLS and PCV2 viral load, as well as improved ADWG in vaccinated versus control pigs.

A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia (Mycoplasma hyopneumoniae) and porcine Circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs

“…Results of this study are in agreement with previous findings regarding the efficacy of the combination vaccine in the face of average PCV2 MDI levels (9.38 log 2 ) [25]. …”

“…On the contrary, control animals had a weaker humoral response. Similar immune response of piglets against natural M. hyo infection after administration of the combination vaccine has been previously reported [25]. …”

Do High Levels of Maternally Derived Antibodies Interfere with the Vaccination of Piglets against Porcine Circovirus Type 2? A Literature Review and Data Analysis

“…From these papers, 10 were excluded based on in-/exclusion criteria. Accordingly, 13 articles [ 4 , 5 , 7 , 8 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ] were finally considered for data collection ( Figure 1 ).…”

Co-Infection of Mycoplasma hyopneumoniae and other swine pathogens

“…Although, some researchers have demonstrated that co-infection with Mhp and PRRSV show no potentiating effect (Van Alstine, Stevenson, & Kanitz, 1996). Thacker and colleagues suggested that the Mhp potentiated and prolonged PRRSV-induced pneumonia clinically, macroscopically and microscopically regardless of the inoculation sequence of infection to both pathogens, whereas PRRSV did not aggravate Mhp infection in piglets when inoculated before Mhp under experimental conditions (Thacker, Halbur, Ross, Thanawongnuwech, & Thacker, 1999;Tzika et al, 2015;Van Alstine et al, 1996). Furthermore, Fablet suggested that, the infection by Mhp was associated with PRRSV seropositive status (Fablet, Marois-Crehan, Grasland, Simon, & Rose, 2016a).…”